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Main Text 
Since WHO declared COVID-19 a global pandemic, measures including lockdown, social distancing, and 
service reprioritization have been imposed to deal with the unprecedented crisis. However, this poses two major 
health risks for cancer patients: compromised cancer care and their increased vulnerability to COVID-19. In 
primary care, family physicians reported delays in delivering cancer screening tests and reluctance to refer 
patients with suspected cancer to secondary care, posing a risk to missing diagnosis (Jones et al., 2020), whereas 
in specialist units downscaling of cancer care has been reported in many countries, including India, Singapore, 
and African countries (Pramesh and Badwe, 2020; Vanderpuye et al., 2020). Systemic treatments are withheld 
due to worries of treatment-induced complications. Curative surgeries could face delays, due to shortage in 
manpower, medical supplies, and high-dependency care capacities (van de Haar et al., 2020). In light of these 
challenges, this Letter addresses the issues of COVID-19 in cancer management and possible measures in 
streamlining future cancer services. 
To ameliorate the crisis, infection control measures and hospital surveillance have been imposed in various 
methods (Table S1). Prior to outpatient visits in the U.S., India, and some European countries, patients would be 
triaged on respiratory symptoms and contact histories. While this was done by telephone calls in Europe (van de 
Haar et al., 2020), out-of-hospital pods have been used in the U.S. and India to screen outpatients (Pramesh and 
Badwe, 2020; Ueda et al., 2020). For inpatients, effective infectious control measures like vigorous 
preadmission surveillance, with regular temperature testing, blood tests, and high-resolution computed 
tomography (HRCT) of lungs, were reported in China (Wang et al., 2020). Others downscaled their services to 
only include new referrals that are acute and emergency (Vanderpuye et al., 2020). However, these safety 
measures would disrupt delivery of cancer care and delay in-patient treatment. Shifting to home deliveries of 
oral medication to cancer patients’ homes has allowed the continuity of care of affected patients (van de Haar et 
al., 2020). However, this temporary change aims to slow disease progression until services return to normal after 
COVID-19 subsides, as well as to reduce risk of treatment-induced complications and unnecessary hospital 
visits. 
For oncological surgery, out-of-hours operations have been a viable coping strategy adopted by worldwide 
cancer centers to catch up on delayed surgeries (Table S1). As of May 2020, our unit in Liverpool has limited 
interruption from COVID-19, and we have successfully sustained thoracic operating capacity by ensuring 
adequate and timely delivery of lung cancer surgery. In Indonesia, surgery eligibility has been adjusted to 
prioritize aggressive cancers, post-neoadjuvant cancers, and timetabling surgeries and outpatient to avoid 
clashes on same days (Brahma, 2020). Although cancer surgery is considered to be essential in the U.S., delays 
to surgery are being managed by oral therapeutics due to lack of personal protective equipment (Ueda et al., 
2020). 
In order to minimize hospital travel, most healthcare providers have started to transition medical practice to 
telemedicine (Table S1). Besides replacing outpatient services with virtual calls (Pramesh and Badwe, 2020; van 
de Haar et al., 2020), in the U.S. healthcare system, automated logic flow bots in emergency departments can 
refer moderate-high risk patients to direct-to-consumer care. These services can be covered by quarantined 
doctors to free up other doctors to perform in-person care (Hollander and Carr, 2020). Before this epidemic, 
tele-oncology has demonstrated similar effectiveness to in-person care at lower costs and has high levels of 
satisfaction in patients and health professionals (Sirintrapun and Lopez, 2018). Telemedicine can facilitate 
cancer management by providing remote chemotherapy supervision, symptom management, and palliative care 
as well as psychological support (Sirintrapun and Lopez, 2018). Thus, we believe that this is a precious 
opportunity for other centers to trial the integration of telemedicine into cancer care while alleviating the 
pressures of COVID-19. 
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Departmental adjustments to improve communication and work efficiency have also been made (Table S1). 
Online channels for communication between staff and webinars at Indian cancer hospitals have been made 
available to facilitate collective decision making and sharing ideas amidst social distancing (Pramesh and 
Badwe, 2020). Additional measures to ensure safety of staff include paid leave given to high-risk staff, such as 
those with comorbidities, those who are taking immunosuppressive medication, or those who are currently 
pregnant. Cancer centers have also used telecommunications for multidisciplinary team meetings to implement 
social distancing (Vanderpuye et al., 2020). Several other countries have employed a segregated team workflow 
in which staff are separated into teams to avoid an entire department being quarantined if one staff member is 
infected (Pramesh and Badwe, 2020; Vanderpuye et al., 2020). 
Overall, the COVID-19 pandemic places stress on standard cancer management pathways, which may 
compromise all aspects of cancer care and can affect multi-organs (Zaim et al., 2020). In order to maintain a 
high quality of care for cancer patients, efficacious leadership frameworks shall be crucial to staff morale, 
communication, and rapid response to incidents. Healthcare providers should prepare for a possible surge in 
cancer cases, especially when it comes to meeting new demands. We believe implementing telemedicine could 
offer short-term relief for the current crisis and provide valuable experience in reshaping future practice. 
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